Hepatocyte growth factor/scatter factor and its receptor, the tyrosine kinase Met, arose late in
evolution and are unique to vertebrates. In spite of this, Met uses molecules such as Gab1 …

Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib,
bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class …

Hsp90 is a chaperone required for the conformational maturation of certain signaling
proteins including Raf, cdk4, and steroid receptors. Natural products and synthetic small …

Studies on signal transduction pathways have generated various promising molecular
targets for therapeutic inhibition in cancer therapy. Receptor tyrosine kinases represent an …

Identification of the key roles of protein kinases in cancer has led to extensive efforts to
develop kinase inhibitors for the treatment of a wide range of cancers, and more than 30 …

PURPOSE: To define outcome data for patients with metastatic renal cell carcinoma (RCC)
with histology other than clear-cell type, including collecting duct (or medullary carcinoma) …

On binding to the cell surface receptor tyrosine kinase (TK) known as c-Met, hepatocyte
growth factor (HGF) stimulates mitogenesis, motogenesis, and morphogenesis in a wide …

Receptor tyrosine kinases have become important therapeutic targets for anti-neoplastic
molecularly targeted therapies. c-Met is a receptor tyrosine kinase shown to be over …

Current anticancer drug development strategies involve identifying novel molecular targets
which are crucial for tumourigenesis. The molecular chaperone heat shock protein (HSP) 90 …

The MET pathway is dysregulated in many human cancers and promotes tumour growth,
invasion and dissemination. Abnormalities in MET signalling have been reported to …